Medicinal Chemistry
Wiley-Interscience (Verlag)
978-0-470-02597-0 (ISBN)
Medicinal Chemistry: An Introduction, Second Edition provides a comprehensive, balanced introduction to this evolving and multidisciplinary area of research. Building on the success of the First Edition, this edition has been completely revised and updated to include the latest developments in the field. Written in an accessible style, Medicinal Chemistry: An Introduction, Second Edition carefully explains fundamental principles, assuming little in the way of prior knowledge. The book focuses on the chemical principles used for drug discovery and design covering physiology and biology where relevant. It opens with a broad overview of the subject with subsequent chapters examining topics in greater depth.
From the reviews of the First Edition:
"It contains a wealth of information in a compact form" ANGEWANDTE CHEMIE, INTERNATIONAL EDITION
"Medicinal Chemistry is certainly a text I would chose to teach from for undergraduates. It fills a unique niche in the market place." PHYSICAL SCIENCES AND EDUCATIONAL REVIEWS
Dr Gareth Thomas, The University of Portsmouth, UK.
Preface to the First Edition xv
Preface to the Second Edition xvii
Acknowledgements xix
Abbreviations xxi
1 An introduction to drugs, their action and discovery 1
1.1 Introduction 1
1.2 What are drugs and why do we need new ones? 1
1.3 Drug discovery and design: a historical outline 3
1.3.1 The general stages in modern-day drug discovery and design 7
1.4 Leads and analogues: some desirable properties 9
1.4.1 Bioavailability 9
1.4.2 Solubility 10
1.4.3 Structure 10
1.4.4 Stability 11
1.5 Sources of leads and drugs 14
1.5.1 Ethnopharmaceutical sources 15
1.5.2 Plant sources 15
1.5.3 Marine sources 17
1.5.4 Microorganisms 18
1.5.5 Animal sources 20
1.5.6 Compound collections, data bases and synthesis 20
1.5.7 The pathology of the diseased state 21
1.5.8 Market forces and ‘me-too drugs’ 21
1.6 Methods and routes of administration: the pharmaceutical phase 21
1.7 Introduction to drug action 24
1.7.1 The pharmacokinetic phase (ADME) 25
1.7.2 The pharmacodynamic phase 32
1.8 Classification of drugs 33
1.8.1 Chemical structure 33
1.8.2 Pharmacological action 34
1.8.3 Physiological classification 34
1.8.4 Prodrugs 35
1.9 Questions 35
2 Drug structure and solubility 37
2.1 Introduction 37
2.2 Structure37
2.3 Stereochemistry and drug design 38
2.3.1 Structurally rigid groups 38
2.3.2 Conformation 39
2.3.3 Configuration 41
2.4 Solubility 44
2.4.1 Solubility and the physical nature of the solute 44
2.5 Solutions 46
2.6 The importance of water solubility 47
2.7 Solubility and the structure of the solute 49
2.8 Salt formation 50
2.9 The incorporation of water solubilising groups in a structure 52
2.9.1 The type of group 52
2.9.2 Reversible and irreversible groups 53
2.9.3 The position of the water solubilising group 53
2.9.4 Methods of introduction 54
2.9.5 Improving lipid solubility 59
2.10 Formulation methods of improving water solubility 59
2.10.1 Cosolvents 59
2.10.2 Colloidal solutions 59
2.10.3 Emulsions 60
2.11 The effect of pH on the solubility of acidic and basic drugs 61
2.12 Partition 63
2.12.1 Practical determination of partition coefficients 65
2.12.2 Theoretical determination of partition coefficients 66
2.13 Surfactants and amphiphiles 66
2.13.1 Drug solubilisation 69
2.13.2 Mixed micelles as drug delivery systems 71
2.13.3 Vesicles and liposomes 72
2.14 Questions 72
3 Structure–activity and quantitative structure relationships 75
3.1 Introduction 75
3.2 Structure–activity relationship (SAR) 76
3.3 Changing size and shape 77
3.3.1 Changing the number of methylene groups in chains and rings 77
3.3.2 Changing the degree of unsaturation 78
3.3.3 Introduction or removal of a ring system 78
3.4 Introduction of new substituents 80
3.4.1 Methyl groups 81
3.4.2 Halogen groups 83
3.4.3 Hydroxy groups 84
3.4.4 Basic groups 84
3.4.5 Carboxylic and sulphonic acid groups 85
3.4.6 Thiols, sulphides and other sulphur groups 85
3.5 Changing the existing substituents of a lead 86
3.6 Case study: a SAR investigation to discover potent geminal bisphosphonates 87
3.7 Quantitative structure–activity relationship (QSAR) 90
3.7.1 Regression analysis 93
3.7.2 The lipophilic parameters 94
3.7.3 Electronic parameters 99
3.7.4 Steric parameters 102
3.8 Questions 110
4 Computer-aided drug design 113
4.1 Introduction 113
4.1.1 Models 114
4.1.2 Molecular modelling methods 115
4.1.3 Computer graphics 116
4.2 Molecular mechanics 117
4.2.1 Creating a molecular model using molecular mechanics 120
4.3 Molecular dynamics 123
4.3.1 Conformational analysis 124
4.4 Quantum mechanics 124
4.5 Docking 127
4.5.1 De novo design 128
4.6 Comparing three-dimensional structures by the use of overlays 130
4.6.1 An example of the use of overlays 132
4.7 Pharmacophores and some of their uses 133
4.7.1 High-resolution X-ray crystallography or NMR 133
4.7.2 Analysis of the structures of different ligands 134
4.8 Modelling protein structures 135
4.9 Three-dimensional QSAR 136
4.9.1 Advantages and disadvantages 140
4.10 Other uses of computers in drug discovery 141
4.11 Questions 143
5 Combinatorial chemistry 145
5.1 Introduction 145
5.1.1 The design of combinatorial syntheses 147
5.1.2 The general techniques used in combinatorial synthesis 148
5.2 The solid support method 148
5.2.1 General methods in solid support combinatorial chemistry 150
5.2.2 Parallel synthesis 152
5.2.3 Furka’s mix and split technique 155
5.3 Encoding methods 157
5.3.1 Sequential chemical tagging 157
5.3.2 Still’s binary code tag system 160
5.3.3 Computerised tagging 161
5.4 Combinatorial synthesis in solution 161
5.4.1 Parallel synthesis in solution 162
5.4.2 The formation of libraries of mixtures 163
5.4.3 Libraries formed using monomethyl polyethylene glycol (OMe-PEG) 164
5.4.4 Libraries produced using dendrimers as soluble supports 164
5.4.5 Libraries formed using fluorocarbon reagents 165
5.4.6 Libraries produced using resin-bound scavenging agents 166
5.4.7 Libraries produced using resin-bound reagents 168
5.4.8 Resin capture of products 168
5.5 Deconvolution 169
5.6 High-throughput screening (HTS) 170
5.6.1 Biochemical assays 171
5.6.2 Whole cell assays 173
5.6.3 Hits and hit rates 173
5.7 Automatic methods of library generation and analysis 174
5.8 Questions 175
6 Drugs from natural sources 177
6.1 Introduction 177
6.2 Bioassays 179
6.2.1 Screening tests 180
6.2.2 Monitoring tests 183
6.3 Dereplication 185
6.4 Structural analysis of the isolated substance 186
6.5 Active compound development 188
6.6 Extraction procedures 189
6.6.1 General considerations 190
6.6.2 Commonly used methods of extraction 191
6.6.3 Cleaning up procedures 195
6.7 Fractionation methods 195
6.7.1 Liquid–liquid partition 196
6.7.2 Chromatographic methods 199
6.7.3 Precipitation 200
6.7.4 Distillation 200
6.7.5 Dialysis 202
6.7.6 Electrophoresis 202
6.8 Case history: the story of Taxol 202
6.9 Questions 206
7 Biological membranes 207
7.1 Introduction 207
7.2 The plasma membrane 208
7.2.1 Lipid components 209
7.2.2 Protein components 211
7.2.3 The carbohydrate component 213
7.2.4 Similarities and differences between plasma membranes in different cells 213
7.2.5 Cell walls 214
7.2.6 Bacterial cell exterior surfaces 217
7.2.7 Animal cell exterior surfaces 218
7.2.8 Virus 218
7.2.9 Tissue 219
7.2.10 Human skin 219
7.3 The transfer of species through cell membranes 220
7.3.1 Osmosis 220
7.3.2 Filtration 221
7.3.3 Passive diffusion 221
7.3.4 Facilitated diffusion 223
7.3.5 Active transport 223
7.3.6 Endocytosis 224
7.3.7 Exocytosis 225
7.4 Drug action that affects the structure of cell membranes and walls 225
7.4.1 Antifungal agents 226
7.4.2 Antibacterial agents (antibiotics) 230
7.4.3 Local anaesthetics 244
7.5 Questions 249
8 Receptors and messengers 251
8.1 Introduction 251
8.2 The chemical nature of the binding of ligands to receptors 252
8.3 Structure and classification of receptors 254
8.4 General mode of operation 256
8.4.1 Superfamily Type 1 259
8.4.2 Superfamily Type 2 260
8.4.3 Superfamily Type 3 263
8.4.4 Superfamily Type 4 264
8.5 Ligand–response relationships 265
8.5.1 Experimental determination of ligand concentration–response curves 266
8.5.2 Agonist concentration–response relationships 267
8.5.3 Antagonist concentration–receptor relationships 268
8.5.4 Partial agonists 271
8.5.5 Desensitisation 272
8.6 Ligand–receptor theories 272
8.6.1 Clark’s occupancy theory 272
8.6.2 The rate theory 277
8.6.3 The two-state model 278
8.7 Drug action and design 279
8.7.1 Agonists 279
8.7.2 Antagonists 281
8.7.3 Citalopram, an antagonist antidepressant discovered by a rational approach 282
8.7.4 b-Blockers 285
8.8 Questions 289
9 Enzymes 291
9.1 Introduction 291
9.2 Classification and nomenclature 293
9.3 Active sites and catalytic action 295
9.3.1 Allosteric activation 297
9.4 Regulation of enzyme activity 298
9.4.1 Covalent modification 298
9.4.2 Allosteric control 298
9.4.3 Proenzyme control 300
9.5 The specific nature of enzyme action 300
9.6 The mechanisms of enzyme action 302
9.7 The general physical factors affecting enzyme action 302
9.8 Enzyme kinetics 303
9.8.1 Single substrate reactions 303
9.8.2 Multiple substrate reactions 305
9.9 Enzyme inhibitors 306
9.9.1 Reversible inhibitors 307
9.9.2 Irreversible inhibition 312
9.10 Transition state inhibitors 318
9.11 Enzymes and drug design: some general considerations 320
9.12 Examples of drugs used as enzyme inhibitors 321
9.12.1 Sulphonamides 321
9.12.2 Captopril and related drugs 323
9.12.3 Statins 326
9.13 Enzymes and drug resistance 329
9.13.1 Changes in enzyme concentration 330
9.13.2 An increase in the production of the substrate 331
9.13.3 Changes in the structure of the enzyme 331
9.13.4 The use of an alternative metabolic pathway 332
9.14 Ribozymes 332
9.15 Questions 332
10 Nucleic acids 335
10.1 Introduction 335
10.2 Deoxyribonucleic acid (DNA) 336
10.2.1 Structure 337
10.3 The general functions of DNA 338
10.4 Genes 339
10.5 Replication 340
10.6 Ribonucleic acid (RNA) 341
10.7 Messenger RNA (mRNA) 342
10.8 Transfer RNA (tRNA) 343
10.9 Ribosomal RNA (rRNA) 345
10.10 Protein synthesis 345
10.10.1 Activation 345
10.10.2 Initiation 346
10.10.3 Elongation 347
10.10.4 Termination 348
10.11 Protein synthesis in prokaryotic and eukaryotic cells 348
10.11.1 Prokaryotic cells 348
10.11.2 Eukaryotic cells 350
10.12 Bacterial protein synthesis inhibitors (antimicrobials) 350
10.12.1 Aminoglycosides 351
10.12.2 Chloramphenicol 355
10.12.3 Tetracyclines 356
10.12.4 Macrolides 359
10.12.5 Lincomycins 360
10.13 Drugs that target nucleic acids 362
10.13.1 Antimetabolites 362
10.13.2 Enzyme inhibitors 368
10.13.3 Intercalating agents 372
10.13.4 Alkylating agents 374
10.13.5 Antisense drugs 377
10.13.6 Chain cleaving agents 379
10.14 Viruses 380
10.14.1 Structure and replication 380
10.14.2 Classification 381
10.14.3 Viral diseases 383
10.14.4 Antiviral drugs 384
10.15 Recombinant DNA technology (genetic engineering) 389
10.15.1 Gene cloning 389
10.15.2 Medical applications 392
10.16 Questions 401
11 Pharmacokinetics 403
11.1 Introduction 403
11.1.1 General classification of pharmacokinetic properties 405
11.1.2 Drug regimens 405
11.1.3 The importance of pharmacokinetics in drug discovery 406
11.2 Drug concentration analysis and its therapeutic significance 407
11.3 Pharmacokinetic models 409
11.4 Intravascular administration 411
11.4.1 Distribution 412
11.5 Extravascular administration 425
11.5.1 Dissolution 428
11.5.2 Absorption 429
11.5.3 Single oral dose 430
11.5.4 The calculation of tmax and Cmax 433
11.5.5 Repeated oral doses 434
11.6 The use of pharmacokinetics in drug design 435
11.7 Extrapolation of animal experiments to humans 435
11.8 Questions 436
12 Drug metabolism 439
12.1 Introduction 439
12.1.1 The stereochemistry of drug metabolism 439
12.1.2 Biological factors affecting metabolism 440
12.1.3 Environmental factors affecting metabolism 443
12.1.4 Species and metabolism 443
12.1.5 Enzymes and metabolism 443
12.2 Secondary pharmacological implications of metabolism 443
12.2.1 Inactive metabolites 444
12.2.2 Metabolites with a similar activity to the drug 444
12.2.3 Metabolites with a dissimilar activity to the drug 444
12.2.4 Toxic metabolites 445
12.3 Sites of action 445
12.4 Phase I metabolic reactions 446
12.4.1 Oxidation 446
12.4.2 Reduction 448
12.4.3 Hydrolysis 448
12.4.4 Hydration 449
12.4.5 Other Phase I reactions 449
12.5 Examples of Phase I metabolic reactions 449
12.6 Phase II metabolic routes 454
12.7 Pharmacokinetics of metabolites 457
12.8 Drug metabolism and drug design 458
12.9 Prodrugs 460
12.9.1 Bioprecursor prodrugs 461
12.9.2 Carrier prodrugs 462
12.9.3 Photoactivated prodrugs 464
12.9.4 The design of carrier prodrug systems for specific purposes 465
12.10 Questions 475
13 Complexes and chelating agents 477
13.1 Introduction 477
13.2 The shapes and structures of complexes 478
13.2.1 Ligands 479
13.2.2 Bridging ligands 483
13.2.3 Metal–metal bonds 483
13.2.4 Metal clusters 483
13.3 Metal–ligand affinities 485
13.3.1 Affinity and equilibrium constants 485
13.3.2 Hard and soft acids and bases 487
13.3.3 The general medical significance of complex stability 488
13.4 The general roles of metal complexes in biological processes 488
13.5 Therapeutic uses 491
13.5.1 Metal poisoning 491
13.5.2 Anticancer agents 494
13.5.3 Antiarthritics 497
13.5.4 Antimicrobial complexes 498
13.5.5 Photoactivated metal complexes 499
13.6 Drug action and metal chelation 501
13.7 Questions 501
14 Nitric oxide 503
14.1 Introduction 503
14.2 The structure of nitric oxide 503
14.3 The chemical properties of nitric oxide 504
14.3.1 Oxidation 505
14.3.2 Salt formation 506
14.3.3 Reaction as an electrophile 507
14.3.4 Reaction as an oxidising agent 507
14.3.5 Complex formation 508
14.3.6 Nitric oxide complexes with iron 508
14.3.7 The chemical properties of nitric oxide complexes 510
14.3.8 The chemistry of related compounds 512
14.4 The cellular production and role of nitric oxide 514
14.4.1 General mode of action 516
14.4.2 Suitability of nitric oxide as a chemical messenger 518
14.4.3 Metabolism 518
14.5 The role of nitric oxide in physiological and pathophysiological states 519
14.5.1 The role of nitric oxide in the cardiovascular system 519
14.5.2 The role of nitric oxide in the nervous system 520
14.5.3 Nitric oxide and diabetes 522
14.5.4 Nitric oxide and impotence 522
14.5.5 Nitric oxide and the immune system 523
14.6 Therapeutic possibilities 524
14.6.1 Compounds that reduce nitric oxide generation 524
14.6.2 Compounds that supply nitric oxide 526
14.6.3 The genetic approach 529
14.7 Questions 529
15 An introduction to drug and analogue synthesis 531
15.1 Introduction 531
15.2 Some general considerations 532
15.2.1 Starting materials 532
15.2.2 Practical considerations 532
15.2.3 The overall design 532
15.2.4 The use of protecting groups 533
15.3 Asymmetry in syntheses 534
15.3.1 The use of non-stereoselective reactions to produce stereospecific centres 535
15.3.2 The use of stereoselective reactions to produce stereogenetic centres 535
15.3.3 General methods of asymmetric synthesis 541
15.3.4 Methods of assessing the purity of stereoisomers 547
15.4 Designing organic syntheses 548
15.4.1 An introduction to the disconnection approach 548
15.4.2 Convergent synthesis 554
15.5 Partial organic synthesis of xenobiotics 556
15.6 Questions 557
16 Drug development and production 559
16.1 Introduction 559
16.2 Chemical development 560
16.2.1 Chemical engineering issues 561
16.2.2 Chemical plant: health and safety considerations 562
16.2.3 Synthesis quality control 563
16.2.4 A case study 563
16.3 Pharmacological and toxicological testing 565
16.4 Drug metabolism and pharmacokinetics 569
16.5 Formulation development 570
16.6 Production and quality control 570
16.7 Patent protection 571
16.8 Regulation 572
16.9 Questions 573
Selected further reading 575
Answers to questions 579
Index 601
| Erscheint lt. Verlag | 1.1.2008 |
|---|---|
| Sprache | englisch |
| Maße | 196 x 253 mm |
| Gewicht | 1389 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Naturwissenschaften ► Chemie | |
| Technik | |
| ISBN-10 | 0-470-02597-2 / 0470025972 |
| ISBN-13 | 978-0-470-02597-0 / 9780470025970 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
